Table 1 Baseline Demographic and Clinical Characteristics
Original cohort | Propensity-score matching cohort | |||||
|---|---|---|---|---|---|---|
Second-Line Treatment | Afatinib (n = 19) | Chemotherapy (n = 89) | p-value | Afatinib (n = 19) | Chemotherapy (n = 19) | p-value |
Age, y (IQR) | 71 (63–82) | 67 (61–74) | 0.107 | 71 (63–82) | 66 (60–74) | 0.144 |
Male, n (%) | 14 (73.7) | 73 (82.0) | 0.404 | 14 (73.7) | 16 (84.2) | 0.426 |
Smoking status, n (%) | 0.875 | 0.721 | ||||
Never smoker | 5 (26.3) | 25 (28.1) | 5 (26.3) | 6 (31.6) | ||
Ex-smoker | 1 (5.3) | 21(23.6) | 1 (5.3) | 3 (15.8) | ||
Current smoker | 13 (68.4) | 44 (49.4) | 13 (68.4) | 10 (52.6) | ||
First-line chemotherapy, n (%) | 0.118 | 0.174 | ||||
Platinum-based | 11 (57.9) | 71 (79.8) | 11 (57.9) | 15 (78.9) | ||
Not platinum-based | 8 (42.1) | 18 (20.2) | 8 (42.1) | 4 (21.1) | ||
Initial clinical stage, n (%) | 0.331 | 0.283 | ||||
IIIB/C | 7 (36.8) | 24 (27.0) | 7 (36.8) | 4 (21.1) | ||
IV | 12 (63.2) | 65 (73.0) | 12 (63.2) | 15 (78.9) | ||
Baseline ECOG PS | 0.135 | 0.221 | ||||
0/1 | 12 (63.2) | 76 (85.4) | 12 (63.2) | 16 (84.2) | ||
≥ 2 | 7 (36.8) | 13 (14.6) | 7 (36.8) | 3 (15.8) | ||
EGFR status, n (%) | 0.577 | 0.560 | ||||
Wild-type | 7 (36.8) | 39 (43.8) | 7 (36.8) | 5 (26.3) | ||
Not tested | 12 (63.2) | 50 (56.2) | 12 (63.2) | 14 (73.7) | ||
PD-L1 expression level, n (%) | 0.278 | 0.530 | ||||
< 1% | 5 (26.3) | 13 (14.6) | 5 (26.3) | 2 (10.5) | ||
1–49% | 2 (10.5) | 27 (30.3) | 2 (10.5) | 3 (15.8) | ||
> 50% | 2 (10.5) | 10 (11.2) | 2 (10.5) | 1 (5.3) | ||
Not tested | 10 (52.6) | 39 (43.8) | 10 (52.6) | 13 (68.4) | ||
Sites of metastatic disease, n (%) | ||||||
Liver | 0 (0) | 10 (11.2) | 0.125 | 0 (0) | 1 (5.3) | 0.311 |
Contralateral lung nodule | 7 (36.8) | 25 (28.1) | 0.448 | 7 (36.8) | 3 (15.8) | 0.141 |
Bone | 3 (15.8) | 25 (28.1) | 0.267 | 3 (15.8) | 5 (26.3) | 0.426 |
Pleural (nodules, effusion) | 2 (10.5) | 15 (16.9) | 0.641 | 2 (10.5) | 5 (26.3) | 0.209 |
Brain | 6 (31.6) | 12 (13.5) | 0.055 | 6 (31.6) | 4 (21.1) | 0.521 |
Other | 0 (0) | 7 (7.9) | 0.718 | 0 (0) | 3 (15.8) | 0.107 |
Comorbidity, n (%) | ||||||
Hypertension | 4 (21.1) | 42 (47.2) | 0.054 | 4 (21.1) | 9 (47.4) | 0.087 |
Chronic kidney disease | 0 (0) | 3 (3.4) | 0.417 | 0 (0) | 1 (5.3) | 0.311 |
Diabetes mellitus | 4 (21.1) | 22 (24.7) | 0.734 | 4 (21.1) | 5 (26.3) | 0.703 |
Hepatic disease | 0 (0) | 9 (10.1) | 0.148 | 0 (0) | 2 (10.5) | 0.214 |
Pulmonary disease | 4 (21.1) | 25 (28.1) | 0.734 | 4 (21.1) | 2 (10.5) | 0.374 |